Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Autor: Frank Jessen, Jan Philipp Bach, Judith Alferink, Isaac Melamed, Jens Wiltfang, Stefan Haag, Yaroslav Winter, Jerome Goldstein, Richard Dodel, Martin R. Farlow, Ralph W. Richter, Kaj Blennow, Stefan Förster, Katharina Buerger, Michael Jacoby, Julius Popp, James C. Stevens, Markus Otto, Frederik Barkhof, Piero Antuono, Peter Bartenstein, Stefan Wietek, Axel Rominger

Publikováno v: Dodel, R, Rominger, A, Bartenstein, P, Barkhof, F, Blennow, K, Forster, S, Winter, Y, Bach, J P, Popp, J, Alferink, J, Wiltfang, J, Buerger, K, Otto, M, Antuono, P, Jacoby, M, Richter, R, Stevens, J, Melamed, I, Goldstein, J, Haag, S, Wietek, S, Farlow, M & Jessen, F 2013, ' Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial ', Lancet Neurology, vol. 12, no. 3, pp. 233-243 . https://doi.org/10.1016/S1474-4422(13)70014-0
The lancet / Neurology 12(3), 233-243 (2013). doi:10.1016/S1474-4422(13)70014-0
Lancet Neurology, 12(3), 233-243. Lancet Publishing Group
The Lancet Neurology, Vol. 12, No 3 (2013) pp. 233-243

Summary Background Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in suc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14627614a4a57861ef6fa044cec2b338
https://research.vumc.nl/en/publications/baa42859-2239-4b58-84af-94323066d666